
    
      This is a multicenter, randomized, double-blind, parallel controlledï¼Œsingle-dose phase I
      study to compare the pharmacokinetic and safety similarities of recombinant anti IgE
      humanized monoclonal antibody (HS632) With omalizumab a in Chinese healthy subjects.
    
  